Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496444 · ClinicalTrials.gov registry record · Phase 1
Azacytidine and Valproic Acid in Patients With Advanced Cancers
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00496444: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00496444 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496444, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer. Secondary Objectives: 1. To perform a preliminary assessment of the histone acetylation and DNA methylation effects of this combination on peripheral blood mononuclear cells (PBMC). 2. To assess the clinical anti-tumor activity (objective response including complete and partial responses) of this combination in patients with advanced cancer, in a descriptive fashion.
Interventions
- DRUG Azacitidine
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496444
The ClinicalTrials.gov registry entry for NCT00496444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00496444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496444 about?
NCT00496444 is a clinical study titled "Azacytidine and Valproic Acid in Patients With Advanced Cancers". Primary Objective: 1\. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer. Secondary Objectives: 1. To perform a preliminary assessment of the histone acetylation and DNA methylation effects of this combination on peripheral blood...
What is the current status of trial NCT00496444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2005-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00496444?
The interventions under investigation include: Azacitidine (DRUG), Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT00496444?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.